CTLA-4 and PD-1 blockade improve the anti-tumor immune response amongst patients with melanoma, NSCLC, and hematological cancers13,42, however, frequently with substantial adverse immunological effects. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.